Cargando…

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoid acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junjian, Zou, June X., Xue, Xiaoqian, Cai, Demin, Zhang, Yan, Duan, Zhijian, Xiang, Qiuping, Yang, Joy C., Louie, Maggie C., Borowsky, Alexander D., Gao, Allen C., Evans, Christopher P., Lam, Kit S., Xu, Jianzhen, Kung, Hsing-Jien, Evans, Ronald M., Xu, Yong, Chen, Hong-Wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030109/
https://www.ncbi.nlm.nih.gov/pubmed/27019329
http://dx.doi.org/10.1038/nm.4070
_version_ 1782454627620356096
author Wang, Junjian
Zou, June X.
Xue, Xiaoqian
Cai, Demin
Zhang, Yan
Duan, Zhijian
Xiang, Qiuping
Yang, Joy C.
Louie, Maggie C.
Borowsky, Alexander D.
Gao, Allen C.
Evans, Christopher P.
Lam, Kit S.
Xu, Jianzhen
Kung, Hsing-Jien
Evans, Ronald M.
Xu, Yong
Chen, Hong-Wu
author_facet Wang, Junjian
Zou, June X.
Xue, Xiaoqian
Cai, Demin
Zhang, Yan
Duan, Zhijian
Xiang, Qiuping
Yang, Joy C.
Louie, Maggie C.
Borowsky, Alexander D.
Gao, Allen C.
Evans, Christopher P.
Lam, Kit S.
Xu, Jianzhen
Kung, Hsing-Jien
Evans, Ronald M.
Xu, Yong
Chen, Hong-Wu
author_sort Wang, Junjian
collection PubMed
description The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoid acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits coactivators SRC-1 and -3 to an AR-RORE to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR gene network. Lastly, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing but not AR-negative xenograft PCa models, and effectively sensitized CRPC tumors to enzalutamide, without overt toxicity in mice. Together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and a potential therapeutic target for advanced PCa.
format Online
Article
Text
id pubmed-5030109
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-50301092016-09-28 ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer Wang, Junjian Zou, June X. Xue, Xiaoqian Cai, Demin Zhang, Yan Duan, Zhijian Xiang, Qiuping Yang, Joy C. Louie, Maggie C. Borowsky, Alexander D. Gao, Allen C. Evans, Christopher P. Lam, Kit S. Xu, Jianzhen Kung, Hsing-Jien Evans, Ronald M. Xu, Yong Chen, Hong-Wu Nat Med Article The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoid acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits coactivators SRC-1 and -3 to an AR-RORE to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR gene network. Lastly, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing but not AR-negative xenograft PCa models, and effectively sensitized CRPC tumors to enzalutamide, without overt toxicity in mice. Together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and a potential therapeutic target for advanced PCa. 2016-03-28 2016-05 /pmc/articles/PMC5030109/ /pubmed/27019329 http://dx.doi.org/10.1038/nm.4070 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Wang, Junjian
Zou, June X.
Xue, Xiaoqian
Cai, Demin
Zhang, Yan
Duan, Zhijian
Xiang, Qiuping
Yang, Joy C.
Louie, Maggie C.
Borowsky, Alexander D.
Gao, Allen C.
Evans, Christopher P.
Lam, Kit S.
Xu, Jianzhen
Kung, Hsing-Jien
Evans, Ronald M.
Xu, Yong
Chen, Hong-Wu
ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
title ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
title_full ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
title_fullStr ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
title_full_unstemmed ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
title_short ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
title_sort ror-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030109/
https://www.ncbi.nlm.nih.gov/pubmed/27019329
http://dx.doi.org/10.1038/nm.4070
work_keys_str_mv AT wangjunjian rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT zoujunex rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT xuexiaoqian rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT caidemin rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT zhangyan rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT duanzhijian rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT xiangqiuping rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT yangjoyc rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT louiemaggiec rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT borowskyalexanderd rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT gaoallenc rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT evanschristopherp rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT lamkits rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT xujianzhen rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT kunghsingjien rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT evansronaldm rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT xuyong rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer
AT chenhongwu rorgdrivesandrogenreceptorexpressionandrepresentsatherapeutictargetincastrationresistantprostatecancer